Biological markers of Mesenchymal Stromal Cells as Predictors of response to
Autologous Stem Cell Transplantation in Patients with Amyotrophic Lateral Sclerosis; an Investigator - Initiated Trial and in Vivo Study.
«For a patient population that typically only sees an overall survival of one to two years after relapse
from autologous stem cell transplantation, the fact that we can report such durable results after five is incredible,» said lead author Robert Chen, MD, of City of Hope Cancer Research Center in Duarte, California.
Dr. Maharaj, the founder and medical director of the Maharaj Institute, was actively involved in the pioneering work
of autologous stem cell transplantation for blood cancer patients in Scotland in the early 1980's.
The technique involves replacing a mutated copy of the gene with a healthy copy in stem cells isolated from the patient, which are then transfused back into the body — a process known
as autologous stem cell transplantation.
Review of «Biological markers of Mesenchymal Stromal Cells as Predictors of response to
Autologous Stem Cell Transplantation in Patients with Amyotrophic Lateral Sclerosis; an Investigator - Initiated Trial and in Vivo Study» from Stem Cells by Stuart P. Atkinson
Standard treatments for symptomatic myeloma include chemotherapy with drugs like bortezomib (Velcade ®), lenalidomide (Revlimid ®), ixazomib (Ninlaro ®), and panobinostat (Farydak ®),
autologous stem cell transplantation, and, in some cases, radiation therapy.
The study, which began in April 2015, administered axi - cel to 108 patients who had failed prior chemotherapy and
autologous stem cell transplantation.
Autologous stem cell transplantation was one of the first forms of immune regenerative treatments to show that patients can have long term disease free survival after the transplant by re-instatement of immune surveillance.